Tourette Wristband Really Work? What We Know About Neupulse
Tourette Wristband Really Work? What We Know About Neupulse? In recent years, there has been a great deal of discussion about Neupulse, a wrist-worn device similar to a smartwatch that has attracted the attention of the international Tourette community. The idea is certainly fascinating: reducing tics through mild, non-invasive electrical stimulation applied to the wrist, without necessarily relying on medication or implanting electrodes in the brain. For many people with Tourette’s, especially those who have experienced ineffective treatments or side effects that were difficult to tolerate, this kind of technology represents enormous hope.
And it is precisely when hope is so great that it becomes essential to clearly distinguish between scientific research, the product available on the market and promises that have not yet been demonstrated. Neupulse is not a scam invented out of nowhere: there are genuine clinical studies and interesting results behind it. But this does not mean that the device currently available for purchase is already an approved medical treatment for Tourette syndrome.
The Most Honest Answer: Promising, but Not Yet a Proven Treatment
Median nerve stimulation has shown the ability to reduce tics in some study participants, both during its application and after several weeks of regular use. The main controlled British study obtained statistically significant results compared with sham stimulation and simply waiting without treatment. This allows us to say that the technology has genuine potential. However, it does not allow us to conclude that it works for everyone, that the benefits last over time or that the product currently sold as Neupulse C has been proven effective in treating Tourette’s. The answer to the question “does it really work?” therefore cannot be an absolute yes or no. The correct answer is this: median nerve stimulation has produced promising results in clinical studies, but the available evidence is still limited and the medical device intended for Tourette’s has not yet completed the regulatory approval process.
How Median Nerve Stimulation Works
The principle behind the technology involves applying small, rhythmic electrical impulses to the median nerve, one of the main nerves running through the wrist and hand. These peripheral signals reach the central nervous system and may influence the activity of brain networks involved in movement and motor control. The first University of Nottingham study, published in 2020, observed that rhythmic median nerve stimulation at approximately 12 hertz could synchronise certain oscillations in sensorimotor areas and reduce the frequency and intensity of tics and the premonitory urge during the sessions.
This led to the idea of transforming the equipment used in the laboratory into a portable device that could be used at home. Describing it as a device that “resets the brain”, however, would be excessive. The stimulation does not restart the nervous system and does not permanently correct the circuits responsible for Tourette’s. Instead, it produces temporary interference with or modulation of nervous activity through a mechanism that has not yet been completely clarified.
The Mechanism May Be Different From What Was Initially Hypothesised
The first proposed explanation was that rhythmic stimulation could synchronise the so-called mu-band brain oscillations involved in movement control. Subsequent studies, however, have complicated the picture. In an independent controlled experiment, median nerve stimulation produced a small improvement in tic intensity, but no significant difference emerged between rhythmic and non-rhythmic stimulation. This means that the effect may not specifically depend on the synchronisation of brainwaves initially hypothesised. The result does not prove that stimulation is useless.
Instead, it shows that we still do not know with certainty why it might work. Other neurophysiological mechanisms, the effect of sensory stimulation itself or, at least in part, factors related to expectations and the treatment context may be involved. Science also progresses in this way: an initial study proposes an explanation, and subsequent studies attempt to confirm, modify or disprove it. Presenting the way Neupulse works as a neurological mechanism that is now completely understood would therefore be premature.
What the Main Clinical Study Showed
The most interesting data come from a double-blind British study involving 121 people with Tourette syndrome or persistent tic disorder. Participants were divided between active stimulation, sham stimulation and a waiting-list group. The treatment was used at home five days a week for four weeks. At the end of the study, the group receiving active stimulation had achieved an average reduction of 7.1 points on the clinical scale used to measure tic severity, equivalent to approximately 35% compared with their initial condition. In the sham stimulation and waiting-list groups, the average reduction was just over two points. The frequency of tics observed during stimulation was also reduced to a greater extent in the active group than in the group receiving sham treatment.
The researchers considered the improvement statistically significant and potentially clinically relevant. According to data later presented by the company, 77% of participants receiving active stimulation reportedly achieved a reduction of at least 25% in the severity of motor tics, while 54% achieved the same result for vocal tics. These figures come from the clinical study, but they are now also reported in the company’s commercial communications and must therefore be read alongside the complete publication rather than as isolated slogans.
An Average Improvement Does Not Mean That It Works for Everyone
The percentages may appear impressive, but they must be interpreted correctly. Saying that 77% of participants achieved at least a certain reduction in motor tics does not mean that the device eliminated tics in 77% of people. It means that, within the group receiving active stimulation, that percentage showed an improvement of at least 25% compared with their own initial condition. Some people may have experienced more noticeable benefits, others modest improvements and still others no useful effect. Tourette’s is extremely variable. Tics change spontaneously over time and are influenced by age, stress, environment, attention, comorbidities and numerous other factors. This is why control groups and sufficiently long observation periods are needed to understand how much of the improvement actually depends on the treatment. The controlled study represents an encouraging signal, but it does not guarantee that an individual person will obtain the same result.
What the Studies Have Not Yet Demonstrated
The main limitation of the available evidence is its duration. The most important trial lasted four weeks. NICE highlighted that there are not yet sufficient data to establish whether the clinical benefit continues beyond this period and requested observations at three, six and possibly twelve months or longer. There are also no adequate comparisons with the treatments normally offered by the health service, and there is insufficient information about the effect on daily life, self-esteem, school or work attendance and quality of life. Tic severity was lower in the group receiving stimulation, but NICE observed that no significant differences had emerged between the groups regarding the impairment and distress caused by the tics. Reducing the number or intensity of movements does not, in fact, automatically produce an equivalent improvement in the person’s life.
There is also limited information about adults, people with very severe tics and individuals with ADHD, obsessive-compulsive disorder, autism, anxiety or mood disorders. These conditions are common among people with Tourette’s but remain insufficiently represented in the available studies. For this reason, it would be incorrect to describe its effectiveness as definitively proven.
Neupulse C and Neupulse M Are Not the Same Thing
This is the most important point for anyone considering a purchase. As of July 2026, the company distinguishes between two products. Neupulse M is the medical device undergoing development and regulatory approval, designed specifically for Tourette’s and tic disorders. Neupulse C, on the other hand, is the general wellness product currently available for pre-order in the United Kingdom. The company itself specifies that Neupulse C is designed to promote calm and relaxation during periods of restlessness or physical tension and that it is not intended to diagnose, treat or cure any medical condition. Delivery is currently estimated for October 2026.
The underlying technology may be similar, and studies on median nerve stimulation have certainly contributed to the development of both products. However, this does not allow the clinical results obtained in the treatment of tics to be automatically transferred to the device sold for wellness purposes. The company itself explicitly separates the two pathways. Buying Neupulse C while believing that you are purchasing an approved medical treatment for Tourette’s therefore means confusing two products that are different from a regulatory perspective and in terms of their stated intended uses.
Why Regulatory Classification Is So Important
A medical device intended to treat a neurological condition must demonstrate that it meets specific requirements relating to safety, performance, manufacturing, control and surveillance. A wellness product can be sold for more general purposes, such as encouraging relaxation or reducing feelings of tension, without being able to officially claim that it treats Tourette syndrome. The difference is not simply a bureaucratic matter. It determines which promises can be made, what evidence must be submitted and which controls must accompany the product. A wellness device does not become a treatment for tics simply because it uses technology studied in people with Tourette’s. The risk is that consumers may read studies concerning the clinical device and attribute the same results to the commercial product, even when the company itself formally avoids presenting it as a treatment.
What NICE Actually Said
In May 2025, NICE assessed Neupulse as part of an evaluation of digital therapies for tic disorders. The British institute recognised the presence of some promising clinical evidence but clarified that Neupulse could not be included in its recommendations because it was still awaiting CE and UKCA authorisations. It therefore published a plan indicating which additional data would need to be collected with a view to a possible future assessment. NICE did not certify that Neupulse was already an approved treatment or one recommended by the British National Health Service. In essence, it said that there was sufficient potential to continue the evaluation, but that regulatory approval, longer-term data, comparisons with standard care and more information about safety and quality of life were required. These are two very different statements.
What We Know About Safety
The published studies have not identified any particularly concerning safety signals. However, NICE specified that the complete information on adverse events had not been published by the company and that the main unwanted effect reported up to that point was skin irritation caused by contact with the electrodes. People with epilepsy were excluded from the study, and NICE indicated that they would probably not be able to use the technology safely. Experts also expressed caution regarding its use in people with functional tics or certain comorbidities because there are insufficient data and the effect could differ from that observed in the participants selected for the trial. “Non-invasive” does not automatically mean “suitable for everyone”. Even stimulation applied to the wrist interacts with the nervous system and must be used in accordance with the correct indications, exclusions and procedures.
The Company’s Involvement in the Studies
Part of the research originated at the University of Nottingham, and the studies were published in peer-reviewed scientific journals. At the same time, Neurotherapeutics, the company developing Neupulse, supplied the devices used in the main trial and funded the work of some members of the group involved in collecting the data. This does not automatically make the results false or unreliable. It is normal for a company to contribute to the studies needed to develop its own device. However, it means that the relationship must be declared and that further independent verification, conducted over longer periods and in different clinical settings, will be particularly important. Science is not evaluated by deciding whether or not to trust the company. It is evaluated by examining the study design, control groups, duration, data transparency and whether other researchers are able to replicate the results.
What to Check Before Buying It
The first question to ask is not only “how much does it cost?” but “what am I actually buying?”. You need to verify the exact name of the product, its classification and its officially stated purposes. Neupulse C is currently presented as a wellness device, while Neupulse M is the medical device that is still undergoing approval. It is also necessary to distinguish study results from customer testimonials. A person may report feeling calmer or having fewer tics, but an individual experience does not demonstrate the general effectiveness of a treatment.
Reviews may be sincere and still not allow us to understand how much of the outcome was caused by the device, expectations, the natural fluctuation of tics or other factors. Before using neuromodulation technology, it is also advisable to discuss it with a doctor or specialist, particularly in the presence of epilepsy, other neurological conditions, ongoing treatments or doubts about the nature of the tics. Finally, the relationship between cost, expectations and uncertainty must be assessed carefully. Spending a significant amount on a wellness product may be a legitimate personal choice, provided that the decision is not made under the belief that one is purchasing an already approved treatment.
So, Does Neupulse Work or Not?
Rhythmic median nerve stimulation may reduce tics in some people with Tourette’s or persistent tic disorder. The main controlled study produced clinically interesting results that were superior to sham stimulation. This is the positive finding and should not be minimised. At the same time, there are still few studies, the maximum duration of the controlled data is short, the mechanism has not been completely clarified and we do not know how long the benefits persist in the medium and long term.
NICE has not yet recommended Neupulse for clinical use, and the Neupulse M medical device is still undergoing approval. The Neupulse C product currently offered to the British public is instead a general wellness device, and the company itself states that it is not intended to diagnose, treat or cure Tourette’s. Neupulse therefore represents one of the most interesting technological avenues currently being studied for tics. But a promising road is not yet a destination that has been reached. Hope is justified. Certainty, at least for now, is not.
If you liked this article, you might also like this one!







